Name: C-lock-GGFG-Dxd
Brand: BOC Sciences
Rating: 5 (1 reviews)

IUPAC Name

N-((S)-10-benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-yl)-2,3-bis(bromomethyl)quinoxaline-6-carboxamide

InChI

InChI=1S/C53H51Br2FN10O11/c1-3-53(75)32-15-41-48-30(22-66(41)51(73)31(32)23-77-52(53)74)47-35(12-10-29-26(2)33(56)16-37(65-48)46(29)47)63-45(70)24-76-25-60-43(68)20-59-50(72)38(13-27-7-5-4-6-8-27)64-44(69)21-57-42(67)19-58-49(71)28-9-11-34-36(14-28)62-40(18-55)39(17-54)61-34/h4-9,11,14-16,35,38,75H,3,10,12-13,17-25H2,1-2H3,(H,57,67)(H,58,71)(H,59,72)(H,60,68)(H,63,70)(H,64,69)/t35-,38-,53-/m0/s1

InChIKey

QKALRJDZWWGYSQ-XLOSCTDISA-N

C-lock-GGFG-Dxd, a cutting-edge drug conjugate in the oncology domain, is tailored to deliver cytotoxic agents to cancer cells with exceptional precision. Here are four key applications of C-lock-GGFG-Dxd:

Targeted Cancer Therapy: Engineered with precision, C-lock-GGFG-Dxd homes in on specific cancer cell receptors, ensuring the exact delivery of the cytotoxic drug Dxd to the tumor site. This targeted strategy minimizes harm to healthy tissues and diminishes side effects compared to conventional chemotherapy. By coupling Dxd with an antibody or a similar targeting moiety, C-lock-GGFG-Dxd achieves heightened effectiveness in annihilating tumors.

Multidrug Resistance Management: Confronting multidrug resistance (MDR) in cancer treatment, C-lock-GGFG-Dxd circumvents the usual drug efflux mechanisms employed by resistant cancer cells. The deployment of a specialized linker (GGFG) guarantees the stable transportation of Dxd specifically to the tumor, bolstering its therapeutic impact even in resistant cancer phenotypes.

Combination Therapy: Integrating seamlessly into combination therapy protocols with other anticancer agents, C-lock-GGFG-Dxd synergizes with additional drugs or treatment methodologies like radiation therapy, amplifying the overall treatment efficacy. By combining C-lock-GGFG-Dxd with other therapeutic modalities, a more comprehensive eradication of tumor cells can be achieved, ultimately enhancing patient outcomes.

Clinical Research and Development: In the realm of clinical research, C-lock-GGFG-Dxd plays a pivotal role in shaping the future of antibody-drug conjugates (ADCs). Researchers leverage its potential to investigate pharmacokinetics, biodistribution, and therapeutic indices, aiming to refine ADC configurations. This research endeavor lays the foundation for the creation of superior targeted oncological interventions with enhanced safety profiles and boosted efficacy.